Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as ...

Officer of Vor Biopharma Inc. (NASDAQ:VOR), recently sold shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The transaction, which occurred on ...

Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical ...

Vor shares are higher lower on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing. Vor Biopharma reveals ...

NEW DELHI: A Buddha Air flight made a VOR landing at Tribhuvan International Airport in Nepal's Kathmandu on Monday after sustaining a flame out from the left engine. The aircraft had 76 people on ...

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...